Standard & Poor’s has affirmed its ‘A-‘ counterparty credit and financial strength ratings and negative outlook on Amedex Insurance Co.
Standard & Poor’s subsequently withdrew the ratings at the company’s request. The ratings reflected Amedex’s good business position as a niche provider of major medical products in Latin America, favorable operating performance, and strong capitalization.
These positive factors are offset by Amedex’s limited size, declining enrollment trends, new business risk through Amedex Bermuda, and high operating expenses, which are the direct consequence of its target market and high level of service provided.
Was this article valuable?
Here are more articles you may enjoy.
US P/C Industry Books Best Result in a Decade but Not All Lines Enjoy Success
Lawsuit Accuses Meta of Using AI to Target Workers With Medical Conditions for Layoffs
What Home Age Actually Tells Us About Claims — And What It Doesn’t
US Considers Creating Finra-Like Watchdog to Vet Top AI Models